The in vivo antitumor activity of CUSP06 was investigated in three xenograft models in which CDH6 expression level are high: PA-1 (Ovarian Cancer), OVCAR-3 (Ovarian Cancer) and 786-O (Renal Cell Carcinoma). Here, CDH6 is linked to hereditary clear cell renal cell carcinoma.